Third Harmonic Bio
Clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation.
Market cap
$245m
Enterprise value
($24m)
Share price
$5.43 THRD
Authorizing premium user...
Clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation.